Trenton
TRENTON, N.J. - Under pressure from the Obama administration, Republican Gov.
TRENTON, N.J. - Under pressure from the Obama administration, Republican Gov.
TRENTON, N.J. - Sanofi-Aventis SA, the world's fourth-biggest drugmaker, said Friday it is eliminating 1,700 jobs in its U.S.
TRENTON, N.J. - As a candidate last year, New Jersey Gov.
More News
- NJ gov. scraps long-planned NJ-NY rail tunnel
- Report: NJ gov. scrapping long planned rail tunnel
- Data firm sees 2011 drug sales rising 5-7 percent
- Johnson & Johnson buying Crucell for $2.41 billion
- NJ mayors seek state help with 2 percent spend cap
- NJ horse racing industry drafts survival plan
- Amgen recalls anemia drugs due to glass flakes
- Bristol-Myers to cut about 840 jobs worldwide
- J&J lawyers: FDA knew of secret 2009 Motrin recall
- House probing possible second secret recall by J&J
- States cutting benefits for public-sector retirees
- Sanofi-Aventis sticking to first offer for Genzyme
- J&J giving $200 million for health of women, kids
- Pfizer, American Kennel Club reach deal
- Merck, J&J arbitration on drug rights starts soon
- Merck schizophrenia drug approved for 2 new uses
- CEO: J&J let down public, must work to build trust
- J&J recalls 2 hip replacement systems for problems
- Johnson & Johnson gets FDA warning on marketing
- Train troubles again strand Northeast commuters
- Johnson & Johnson recalls contact lenses overseas
- Report: J&J creates new quality control position
- Vaccine sales up 16 pct in 2009, still growing
- Northeast Amtrak delays from downed NJ tree abate
- Downed tree in NJ leads to Northeast Amtrak delays
- Merck rebuying its former drug ingredient factory
- Merck discloses probe of foreign sales practices
- Sanofi CEO targeting everything but blockbusters
- Merck and Sanofi name CEO of animal medicine unit
- Merck pairs up with Chinese drugmaker Sinopharm
- Momenta receives OK for generic version of Lovenox
- Q2 sales, profit improve for 3 major drugmakers
- Bristol-Myers posts 6 percent drop in 2Q profit
- New FDA report shows multiple lapses at J&J plant
- Pfizer halts third study of experimental pain drug
